Business Wire

NY-BORN

2.3.2021 15:14:05 CET | Business Wire | Press release

Share
BORN Expands With Alkeon B2B Market Network Platform Transforming Commercial Models, Starting With the Trade Show Industry

BORN, announces the expansion of innovative B2B subsidiary Alkeon, the world's first global SaaS market-network combining content, community, and commerce to connect buyers and sellers through a best-in-class platform, powered by machine learning. The 2020 pandemic generated a tremendous and immediate need for companies of all categories to pivot at a moment’s notice, with over 10,000 global trade shows completely upended due to cancellations of physical events. BORN, a purpose driven lifestyle company dedicated to reimagining the discovery, transaction and connection of the B2B and B2C communities, found an opportune moment to quickly scale and enhance their technology solutions. The company formally established Alkeon, an enterprise dedicated to supporting the needs of companies who are adapting to the current and future landscapes and need the right partner to support them through the process.

Combining aesthetic and function to create designed technology, Alkeon is a market-network company that enables brands to create an always-on commercial model, digitally optimize their existing infrastructure, capture detailed audience insights and more. Starting with the immediate needs of the global trade show market, Alkeon represents over 15,000 buyers and 150,000 new products by the end of the year. The B2B solution has seen hyper growth and solidified contracts from some of the most influential global trade shows including Tranoï (part of GL Events), Cosmoprof, Brand Assembly, Reassemble, Esxence and Bridal Harrogate.

Founder and CEO of BORN, Jean-Christophe states, “We have seen gaps in the B2B and B2C supply chains for several years, with many aspects of both still operating with analogue systems that lack the benefits of full digital capabilities, audience intelligence and ways to expand and enhance traditional commercial models. The last year has made these gaps stark, leaving many companies in a position to innovate quickly in order to survive. The trade show audience was not only deeply disrupted, but is crucial for global commerce. The tech solutions that we’ve developed have implications for several industries, but we chose to focus on this important category that supports economies around the world. Longterm, businesses, including trade shows, will need a hybrid model that combines the best of technology with the great benefits of physical interaction. We’re creating the solutions for now and well into the future.”

Alkeon’s technology platform empowers trade shows to digitally transform their business, and expand their business internationally with buyers, agents, showrooms and distributors. Brands using BORN's Alkeon service can select a package that ranges from $99 a month to $15,000 a year with various offerings, including intelligent matchmaking, a suite of connection tools such as in-app messaging and video meetings, actionable insights about their business such as buyer engagement and trending product reports. Alkeon offers buyers best-in-class product discovery experience powered by machine learning, delivering personalized product recommendations, curated product lists, and the ability to save products.

“Early on, we asked ourselves the question, “Why can’t B2B be beautiful?”. So we set out with the goal to delight wholesale buyers with a refined, feature-rich product discovery and purchase experience typically reserved for direct-consumer experiences.” - Brendan Wypich, Chief Design & Product Officer.

The platform provides a sleek interface for each brand to present their story and products so that buyers can make quick and informed business decisions. Alkeon streamlines a brand’s workflows by providing full transparency and clear tracking of buyer order flows from initial interest through to purchase order all while staying in constant contact with the buyer. The result is a simplified wholesale buying process that future-proofs the brand’s operations while scaling their business footprint.

BORN began developing the Alkeon technology well before the pandemic hit. Alkeon offers a pleasing and educational discovery experience along with a seamless infrastructure. With quick expansion, BORN and Alkeon will chart the course for the future of retail and wholesale, using the best of the latest technology to learn and adapt, curate and personalize and allow for broader market access. The benefits of the technology have game-changing implications for tradeshows, showrooms, brands, media companies, press agents and buyers.

About BORN:

BORN specializes in digital, data-led solutions to digitize retail supply chains and reimagine discovery and transaction online. BORN owns Alkeon, a suite of B2B solutions and software products that digitize tradeshows and showrooms, as well as Born.com, a platform connecting thousands of luxury design-led brands with premium retailers. BORN is led by CEO Jean-Christophe Chopin, ex-founder of E*Trade EU and Verisign EU.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye